Important note
This AI stock analysis for Recursion Pharmaceuticals is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Recursion Pharmaceuticals - AI Stock Analysis
Analysis generated September 3, 2025
Recursion Pharmaceuticals is a biotechnology company focused on using artificial intelligence and a robust inferential search technology to discover novel treatments for some of the most complex and underserved therapeutic areas. The company integrates experimental biology, chemistry, and computational science to accelerate drug discovery and development. This innovative approach positions Recursion as a potentially disruptive player in the biopharmaceutical industry.
Fundamental Analysis
Recursion Pharmaceuticals has demonstrated noteworthy figures in its recent financial performance.
The revenue for the last quarter stood at $19 million, which represents a significant increase of 30.37% compared to the previous quarter and an increase of 33.34% from the same quarter last year. These numbers highlight strong positive growth and hint at effective business execution and product demand.
Net income for the last quarter was $172 million, showing a growth of 15.11% from the previous quarter. However, compared to the same quarter last year, there is a marked decrease of 76.23%, which raises concerns about profitability volatility and underlying cost structures. Similarly, EBITDA for the last quarter was $176 million, up 3.60% from the previous quarter but down 96.53% year-over-year (YoY), another point of concern for long-term profitability.
Additionally, the fact that company insiders have sold shares could be perceived as a bearish signal, suggesting that insiders may not be confident about the company's short-term prospects.
Technical Analysis
Recursion Pharmaceuticals' stock price is currently at $4.66, which is a decrease of 17.96% from the previous month and down 23.61% compared to a year ago. This downward trend can be concerning for both short-term and long-term investors.
The simple moving average over the last 10 days (SMA10) is $4.75, slightly lower than the previous SMA10 of $4.78, indicating a potential downward trend. Furthermore, with an RSI of 80.9, the stock appears to be in an overbought condition, suggesting bearish sentiment among traders.
Alternative Data Analysis
Alternative data allows for more nuanced insights into Recursion Pharmaceuticals' operational growth and market sentiment.
Employee sentiment towards the business outlook remains neutral. However, the company has 19 open positions, an increase of 73% in the last few months, indicating a push towards expansion and potentially a positive business outlook.
Customer acquisition metrics are strong, with an estimated 56,000 visitors to their webpage, up 40% in recent months, which can lead to more customer engagement and potential sales. Social media presence also shows growth, with 15,000 Twitter followers, up 6%, reflecting increased interest in the company.
AltIndex’s AI score for Recursion Pharmaceuticals stands at 71, suggesting a buy signal, indicating overall positive sentiment derived from an amalgamation of fundamental, technical, and alternative data sets.
Conclusion and Recommendation
Recursion Pharmaceuticals presents a mixed bag for potential investors. From a fundamental perspective, the growth in revenue is promising, but significant decreases in net income and EBITDA are concerning. Technically, the stock appears to be on a downward trend, and although this might seem bearish, it might also present an opportunity to buy at a lower price point if other fundamentals improve.
On the alternative data front, increasing job openings, website traffic, and social media engagement could indicate future growth and increased market presence.
Considering the AltIndex AI score of 71, which is a buy signal, a cautiously optimistic approach is advisable. Monitoring the company's ability to stabilize and grow its profitability, while keeping an eye on market conditions and insider actions, would be prudent steps for investors. Based on this analysis, Recursion Pharmaceuticals appears to warrant a speculative "buy" recommendation, particularly for those who believe in the potential of their innovative approach in biotechnology.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.